REVIEW

Menopause-associated risk of cardiovascular disease

Panagiotis Anagnostis1, Irene Lambrinoudaki2, John C Stevenson3 and Dimitrios G Goulis1

1Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
22nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
3National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield Hospitals, Guy's and St Thomas’ NHS Foundation Trust, London, UK

Correspondence should be addressed to P Anagnostis: anagnostis@auth.gr

Abstract

Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50–52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens.

Key Words

- menopausal hormone therapy
- early menopause
- premature ovarian insufficiency
- cardiovascular disease

Endocrine Connections
(2022) 11, e210537

Introduction

Cardiovascular disease (CVD) is the leading cause of death in women, involving 50% of cases, with 20% attributed to ischemic heart disease (IHD) and 13% to stroke (1). This is also the case for women younger than 65 years, with 26% of deaths assigned to CVD (1). Except for obstructive coronary heart disease (CHD), other major causes of IHD in middle-aged women include coronary artery spasm and coronary microvascular dysfunction (2). Although IHD in females occurs 7–10 years later compared with males, mostly due to the protective effect of estrogens on the atherosclerotic process, there is a steady increase in this risk after the transition to menopause (2). This is mostly evident in women with early menopause (EM; defined as age at menopause <45 years) or premature ovarian insufficiency (POI; defined as age at menopause <40 years) (3).

The aim of this narrative review was to provide an evidence-based approach to the menopause-associated CVD risk. Moreover, the effect of menopausal hormone therapy (MHT) on this risk is also discussed.
Does transition to menopause predispose to higher CVD risk?

Menopause, defined as the completion of 12 months since the final menstrual period (FMP) or at the time of bilateral oophorectomy, is the consequence of follicle depletion which results in estrogen deficit (4). Epidemiological evidence has shown that menopausal transition is associated with a higher prevalence of CVD risk factors, such as central adiposity, atherogenic dyslipidemia, glucose intolerance, arterial hypertension (AH) and non-alcoholic fatty liver disease (NAFLD), compared with premenopausal status (5).

In detail, transition to menopause leads to body fat redistribution toward the male pattern of visceral adiposity (6, 7). Indeed, the onset of menopause is followed by a reduction in fat oxidation and a decrease in energy expenditure, without changes in energy intake (7). In studies using dual-energy X-ray absorptiometry, CT or MRI, postmenopausal women have 36% more thoracic fat and 49% greater intra-abdominal fat area compared with premenopausal women (8). These differences were independent of age and total fat mass (8). Moreover, biopsy studies in postmenopausal women have shown hypertrophy of adipocyte cells both in subcutaneous and visceral adipose tissue, as well as increased inflammation and fibrosis, compared with premenopausal women (9). One mechanism for the postmenopausal body fat redistribution may be the upregulation of adipose tissue lipoprotein lipase activity and a lower degree of lipolysis, due to the decrease in estrogen concentrations (10, 11). The loss of 17ß-estradiol (17ß-E2) activation of estrogen receptor (ER) type α (ERα) in neurons of the ventromedial nucleus of the hypothalamus, which regulates adipose tissue distribution, constitutes another mechanism (12).

These changes in adipose tissue may lead to increased insulin resistance (up to 50%) in postmenopausal compared with premenopausal women (13). ERα and ER type β (ERβ) promote β-cell survival and secretion, as shown in animal studies (7). Pancreatic insulin secretion is also reduced by 50% in postmenopausal compared with premenopausal women, irrespective of BMI and age (13). Except for the pancreas, estrogen acts on the liver (via ERα) and reduces gluconeogenesis (14). It also increases glucose uptake in fatty tissue and muscles, mainly via translocation of glucose transporter 4 (14).

On a clinical level, plasma glucose concentrations may be either not affected (13) or dysregulated toward impaired glucose tolerance (IGT) in women who enter menopause (15). The estimated annual incidence of IGT after menopause is 6%, independent of BMI, waist-hip ratio, blood pressure, family history of diabetes mellitus (DM) type 2 (T2DM), age at menopause and lipid profile (15). However, a recent meta-analysis showed that postmenopausal women with a history of EM or POI demonstrate a higher risk for T2DM, compared with those with a normal age at menopause (>45 years) (odds ratio (OR) 1.12, 95% CI 1.01–1.20 and 1.53, 95% CI 1.03–2.27), respectively (16).

Regarding blood pressure (BP), epidemiological evidence suggests an increase after the onset of menopause (17). However, it is not clear if this is a consequence of menopause per se or the aging process, due to reduced vascular elasticity and increased prevalence of atherosclerosis in older ages (6). The contribution of other factors, such as obesity, smoking and low physical activity should be taken under consideration (17). In any case, a steeper increase in systolic BP in postmenopausal women (18) has been reported as well as a higher sympathetic activity compared with their male counterparts (19). Furthermore, a recent meta-analysis showed a slight but significant increase in the risk of AH in women with EM compared with those with an age at menopause >45 years (OR 1.10, 95% CI 1.01–1.19) (20). Plausible pathogenetic mechanisms include the production of vasoconstrictive factors, such as endothelin and angiotensinogen, as the result of the decline in estrogen concentrations, and a lower estrogen-to-androgen ratio during menopause (21).

What is of importance regarding the menopause-associated CVD risk is the changes in lipid profile during the transition to menopause. Concisely, these include an increase in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and a decrease in high-density lipoprotein cholesterol (HDL-C) concentrations (22). The latter is mainly attributed to the HDL-C2 subfraction (22). Notably, except for these changes in lipid profile, atherogenic changes in apolipoprotein concentrations and their ratios have also been reported after the onset of menopause. These include an increase in apolipoprotein B (apoB) concentrations and LDL-C/apoB ratio in postmenopausal women, which are evident from the age of 50–55 years, converging with and exceeding the respective values in men (23). Moreover, despite the rise in apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II) concentrations in postmenopausal compared with premenopausal women, the HDL-C/apoA-I and HDL-C/apoA-II ratios decrease to the lowest degree seen in men, suggesting a lower cholesterol content of HDL particles (23). Regarding lipoprotein (a) (Lp(a)), an independent risk factor for atherosclerotic CVD (24),
inconclusive data exist as to whether this increases after menopause (25).

Furthermore, dyslipidemia and insulin resistance facilitate an increased influx of free fatty acids to the liver and enhance the development of NAFLD (26). Except for estrogen deficit, the relative androgen excess and decrease in sex hormone-binding globulin also contribute to increased abdominal adipose mass and ensuing NAFLD (27). Postmenopausal women are at a two-fold increased risk of NAFLD compared with premenopausal women (27). The respective prevalence of NAFLD in women <45 years, 45–55 and >55 years is 5.3, 18.8 and 27.8%, respectively (28). In cases of obesity, it rises to 48.4% (28). More than 50% of postmenopausal women with T2DM suffer from NAFLD (26). The prevalence of non-alcoholic steatohepatitis is also high in women >55 years (13.2%) and even higher in those with obesity and NAFLD (14.9%) (28).

Is there an independent association between menopause and increased risk of CVD events?

The data mentioned before suggest an acquisition of an atherogenic profile in women during and after the transition to menopause predisposing them to increased CVD risk. Interestingly, endothelial dysfunction starts in the early postmenopausal period, before signs of subclinical atherosclerosis occur, possibly accounting for the ‘undetermined’ chest pain and dyspnea, often attributed to stress or to menopausal symptomatology (2). In addition, these women are at two-fold increased risk of IHD (2). Inflammatory co-morbidities, such as autoimmune rheumatic (i.e. rheumatoid arthritis, systemic lupus erythematosus) and endocrine disorders (thyroid dysfunction) augment CVD risk in women around menopause (2).

Whether this increased risk is translated into an equivalent risk of CVD events in postmenopausal women, irrespective of the effect of chronological aging, has not been established, as the relevant studies show inconsistent data (29, 30, 31). On the other hand, both EM and POI have been associated with increased CVD morbidity and mortality, mainly due to IHD. According to a meta-analysis, published in 2016 (32 studies; n = 310,329 postmenopausal women), the history of EM is associated with a 1.5-fold increased risk for IHD (relative risk (RR) for overall IHD 1.50, 95% CI 1.28–1.76) compared with normal age at menopause (>45 years) (32). This was also the case for fatal IHD (RR 1.11, 95% CI 1.03–1.20), CVD mortality (RR 1.19, 95% CI 1.08–1.31) and all-cause mortality (RR 1.12, 95% CI 1.03–1.21). However, no association with overall stroke risk and stroke mortality was observed (32).

With respect to POI, two meta-analyses published in 2016, confirmed these results. In particular, the history of POI augments the risk of all-cause and IHD mortality by 39% (pooled RR 1.39, 95% CI 1.10–1.77) and 48% (pooled RR 1.48, 95% CI 1.02–2.16), respectively, compared with normal age at menopause (>45 years) (33). This was also the case with another meta-analysis (10 studies; n = 190,588 postmenopausal women), showing an increased risk of IHD (hazard ratio (HR) 1.69, 95% CI 1.29–2.21) and total CVD morbidity or mortality (HR 1.61, 95% CI 1.22–2.12) (34). As with EM, the history of POI was not associated with an increased risk of stroke (33, 34). A recent cohort study from the UK (n = 144,260 postmenopausal women, aged 40–69 years) showed an increased risk for CVD for natural and surgical premature menopause (<40 years) compared with menopause at an age >40 years (HR 1.36, 95% CI 1.19–1.56 and 1.87, 95% CI 1.36–2.58, respectively, after adjustment for conventional CVD risk factors and the use of MHT). This was again mainly attributed to IHD (35).

Does menopausal hormone therapy reduce CVD risk?

Menopausal hormone therapy and CVD risk factors

Since menopause augments CVD risk, at least in women with EM and POI, the spontaneously arising question is whether MHT could reduce this risk. Accumulative body of evidence supports the notion that MHT may ameliorate most CVD risk factors, such as visceral adiposity, dyslipidemia and glucose homeostasis to various extent, depending on the formulation used (estrogen type, dose, route of administration and type of progestogen) (6). Briefly, estrogen may decrease TC, LDL-C, Lp(a) and increase HDL-C concentrations in a dose-dependent manner (6, 7, 36). These changes are more pronounced with conjugated equine estrogen (CEE) compared with 17β-E2, the latter being higher with oral than with transdermal regimen (6, 7, 36). However, TG concentrations may increase with oral estrogen, whereas they may either decrease or remain stable with the transdermal route (6, 7). Nevertheless, the latter does not affect the coagulation system and is not associated with an increased risk of venous thromboembolism (VTE) in contrast to the oral regimen (37, 38).

MHT may exert either a slight reduction or no effect on BP and BMI (6, 7) and it may reduce visceral adiposity and waist circumference (6, 7). Regarding glucose metabolism,
MHT improves glucose homeostasis, by increasing insulin sensitivity and secretion, as well as glucose uptake by the muscles (7). It may also reduce the risk of T2DM by 30% (7, 38). Both oral and transdermal estrogen demonstrate a favorable effect on glucose metabolism, although oral CEE exert a more pronounced effect at equivalent doses (7).

Regarding the effect of MHT on NAFLD, current evidence shows inconclusive results (26).

Concerning progestogens, they seem to modify the effect of estrogen on the CVD risk factors mentioned above. Medroxyprogesterone acetate (MPA) and levonorgestrel may attenuate this effect, whereas low-dose norethisterone acetate and dydrogesterone are neutral (7). In general, micronized progesterone or dydrogesterone are the preferred progestogens due to their neutral effect on lipid profile (39).

### MHT and CVD events

Regarding CVD events, several observational studies, especially during the period 1980–2000, have shown a beneficial effect of MHT on CHD risk (40, 41). However, the concept of CVD primary prevention by MHT had to be tested in a randomized controlled trial setting (RCTs). The hallmark RCT, designed to investigate the effect of MHT on CVD (with CHD as the main outcome) and breast cancer risk, was the Women’s Health Initiative (WHI) Study. This study had two arms; the first (WHI-1) compared the effect of CEE 0.625 mg/day plus MPA 2.5 mg/day (n = 8506) with that of placebo (n = 8102) in postmenopausal women (50–79 years old) with an intact uterus (42). This study was early terminated (at 5.2 years) due to evidence of increased risk of invasive breast cancer (HR 1.26, 95% CI 1.00–1.59). The preliminary results from the study showed that the estimated HR for IHD, total CVD, stroke and VTE was 1.29 (95% CI 1.02–1.63), 1.22 (95% CI 1.09–1.36), 1.41 (95% CI 1.07–1.85) and 2.11 (95% CI 1.58–2.82) and, respectively. However, MHT was associated with a reduced risk of colorectal cancer (HR 0.63, 95% CI 0.43–0.92) hip (HR 0.66, 95% CI 0.45–0.98) and total fractures (HR 0.76, 95% CI 0.69–0.85) (42). Notably, when the final results of WHI-1 were published, the risk for CHD risk was not significant (HR 1.24, 95% CI 0.97–1.60) (43).

The second arm (WHI-2) recruited 10,739 postmenopausal women, aged 50–79 years, with a history of hysterectomy, who were randomized to CEE 0.625 mg/day (n = 5310) or placebo (n = 5329). MHT increased the risk of stroke (HR 1.39, 95% CI 1.10–1.77) and VTE (1.33, 95% CI 0.99–1.7), without any effect on the risk of CHD and colorectal cancer. Interestingly, it decreased the risk of breast cancer (HR 0.77, 95% CI 0.59–1.01), hip (HR 0.61, 95% CI 0.41–0.91) and total fractures (HR 0.70, 95% CI 0.63–0.79) (44).

Nonetheless, an in-depth look into the WHI trials can reverse their first negative impression. One should take into consideration that the mean participants’ age was 63 years, with two-thirds being older than 60 years. When women were stratified according to their age, a marginally non-significant reduction in CHD risk was observed in the age group of 50–59 years (HR 0.56, 95% CI 0.3–1.03), with CEE alone, compared with no effect in the other age groups (60–69 and 70–79 years) (44). The respective absolute risk stratified by age was ten and five fewer cases for fatal and non-fatal CHD per 10,000 women/year for the ages of 50–59 and 60–69 years, respectively, in excess of four cases for those 70–79 years old (44). However, in the estrogen-alone arm, there was a significant reduction in a composite CHD outcome in those initiating treatment below age 60 years, and with long-term follow-up post-intervention there was a significant reduction in CHD events compared with placebo (43).

Moreover, a prospective Danish cohort (n = 698,098 postmenopausal women, aged 51–69 years), published 5 years after the WHI, showed no increased risk of myocardial infarction (MI) (RR 1.03, 95% CI 0.95–1.11) for current MHT users compared with never users (45).

In subgroup analyses, this risk increased with a longer duration (>4 years) (RR 1.81, 95% CI 1.19–2.77) (45). Interestingly, the risk for MI decreased (RR 0.62, 95% CI 0.42–0.93) with transdermal unopposed estrogen (compared with women who never used MHT) and it was also lower than that of oral regimen (45).

A Cochrane meta-analysis, published in 2015, showed a decreased risk of CHD (RR 0.52, 95% CI 0.29–0.96) and all-cause mortality (RR 0.70, 95% CI 0.52–0.95) if MHT was commenced within 10 years since menopause, raising the issue of ‘window of opportunity’ (46). No effect on the risk of stroke was observed, although the risk of VTE remained high (RR 1.74, 95% CI 1.11–2.73) (46).

The timing hypothesis was confirmed in more recent RCTs, such as the Early vs Late Intervention Trial with Estradiol study, in which 643 apparently healthy postmenopausal women were randomized to 17β-E2 (1 mg/day plus vaginal gel of progesterone for non-hysterectomized women) or placebo. After a median of 5 years, 17β-E2 decreased the rate of carotid intima-media thickness progression only in early postmenopausal women (<6 years since their FMP) compared with placebo. No difference in late postmenopausal women was observed in this regard (47). This cardioprotective effect of MHT in...
early postmenopausal women was replicated in the Danish Osteoporosis Prevention Study, including 502 women, 45–58 years old. According to its findings, 17β-E₂ at a dose of 2 mg/day was associated with a 52% reduction in the risk of the composite CVD outcome (HR 0.48, 95% CI 0.26–0.87). There was no difference in the risk of VTE, stroke or breast cancer between groups (48).

However, another RCT, the Kronos Early Oestrogen Prevention Study, which recruited 728 women (42–58 years of age), failed to demonstrate any benefit of estrogen (either CEE 0.45 mg/day or transdermal 17β-E₂ 50 μg/day) over placebo on coronary artery calcium score, another surrogate marker of atherosclerotic CVD. The duration of the trial was quite short (48 months) (49). Moreover, MHT has no effect on CVD risk in the setting of secondary prevention, as shown in the Heart and Estrogen/progestin Replacement Study (HERS) (50).

Based on the evidence presented above, most international societies converge regarding the indications for MHT (38, 51, 52). These include cases of EM or POI, as well as postmenopausal women <60 years old or within 10 years since menopause and at low-to-moderate CVD risk, for menopausal symptom relief, since the benefits of MHT outweigh potential risks (38, 51, 52). MHT is currently contraindicated in women at high CVD risk or for the sole purpose of primary or secondary prevention of CHD (38, 51, 52). In cases of moderate risk of CVD, transdermal estradiol should be preferred as first-line treatment, either alone for women without a uterus or in combination with micronized progesterone or dydrogesterone, due to their neutral effect on CVD risk factors and coagulation parameters (38). This is also the case for women at high VTE risk (38).

Clinicians should also consider that CVD mortality increases after MHT discontinuation, concerning either IHD (standardized mortality ratio (SMR) 1.26, 95% CI 1.16–1.37) or stroke (SMR 1.63, 95% CI 1.47–1.79), during the first post-treatment year. However, this risk is dissipated thereafter (SMR 0.75, 95% CI 0.72–0.78 and 0.89, 95% CI 0.85–0.94). This risk is also higher in women <60 years, but not in older women who discontinue MHT (SMR 1.94, 95% CI 1.51–2.48) (53).

The main concern with MHT is breast cancer risk, which is mostly attributed to progestogen. It is relatively lower with newer regimens, such as micronized progesterone and dydrogesterone (54) and seems to disappear after MHT discontinuation (38, 51, 52). According to a recent systematic review, MHT containing micronized progesterone does not increase breast cancer risk for up to 5 years of treatment. Limited evidence indicates an increased risk only if MHT is applied for >5 years (55). The key points regarding the effect of MHT on CVD risk are summarized in Table 1.

Special issues

Specific consideration should be paid to women with T2DM or dyslipidemia. In general, oral estrogens may be administered in peri-or recently postmenopausal women with new-onset T2DM and at low CVD risk. However, in the sub-population of obese postmenopausal women with T2DM and at moderate CVD risk, transdermal 17β-E₂ is the preferred treatment, either as monotherapy or with a progestogen with minimal effects on glucose metabolism, such as micronized progesterone, dydrogesterone or transdermal norethisterone (56).

With respect to dyslipidemia, oral estrogens induce a more prominent effect on TC, LDL-C, Lp(a) and HDL-C concentrations, compared with transdermal ones. However, the latter should be used in women with hypertriglyceridemia (39). In any case, the 10-year risk of fatal CVD should be assessed to set the optimal LDL-C target and prescribe a lipid-lowering medication (i.e. statins, ezetimibe) when necessary (39). Regarding the progestogen, priority should be given to micronized progesterone or dydrogesterone, due to their neutral effect on lipid profile (39).

Table 1 The effect of MHT on CVD risk.

| MHT improves lipid profile, glucose homeostasis and visceral adiposity. |
| The evidence for an effect of MHT on BP and NALFD is inconclusive. |
| Transdermal estradiol is preferred over oral regimens, since the former does not increase triglyceride concentrations and is not associated with increased VTE risk. |
| MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period. |
| (<60 years or within 10 years since the FMP). |
| In women with POI, MHT should be administered at least until the average age of menopause (50–52 years). |
| CVD risk increases after MHT discontinuation. |
| MHT is not currently recommended in women at high CVD risk or with a history of VTE or for the sole purpose of CVD prevention. |
| The risk of breast cancer is minimized with the use of micronized progesterone or dydrogesterone. |

BP, blood pressure; CVD, cardiovascular disease; FMP, final menstrual period; MHT, menopausal hormone therapy; NALFD, non-alcoholic fatty liver disease; POI, premature ovarian insufficiency; VTE, venous thromboembolism.
Assessment of CVD risk in postmenopausal women

In general, clinicians need to consider the patient’s total CVD risk before initiating MHT. First, lipid profile (TC, LDL-C, TG and HDL-C), fasting plasma glucose and BP should be assessed in every postmenopausal woman. The next step is to estimate the woman’s 10-year risk for fatal CVD, according to the Systematic Coronary Risk Estimation (SCORE) system, proposed by the 2019 European Society of Cardiology / European Atherosclerosis Society guidelines (57). However, the SCORE system has some limitations, such as the sole inclusion of fatal ASCVD outcomes and the substantial variations of CVD risk across countries, which result in an underestimation of the individual’s risk. Therefore, it has recently been updated to SCORE2, for individuals aged 40–69 years (58), and to SCORE2-Older Persons (SCORE2-OP) risk model, for those >65 years old (59). This attempt was made on the basis of 10-year fatal and non-fatal ASCVD risk estimation in different European regions (58). Of note, non-HDL-C instead of TC is used in these two models (58, 59).

This updated SCORE is now recommended for CVD risk estimation in apparently healthy individuals without established ASCVD, DM, CKD, genetic lipid (FH) or BP disorders. These five states assign the patient at ‘very high’ or ‘high’ CVD risk (60). The former is considered in cases with established ASCVD, <50 years old with SCORE2 >7.5%, 50–69 years old with SCORE2 >10% or ≥70 years with SCORE2-OP >15% (60). On the other hand, an individual is considered at ‘high risk’ if his/her SCORE2 is 2.5–7.5%, 5–10% and 7.5–15% in cases of <50, 50–69 and >70 years of age, respectively (60). In ‘very high’ and ‘high’ risk patients, the LDL-C target is set at <55 mg/dL (1.4 mmol/L) and <70 mg/dL (1.8 mmol/L), respectively, with an additional need of ≥50% reduction in LDL-C concentrations (57). Furthermore, the term ‘low-to-moderate risk’ is used for women or men <50 years, 50–69 or ≥70 years with a SCORE2 or SCORE-OP of <2.5, <5 or <7.5%, respectively. Patients with well-controlled DM of <10 years duration, with no evidence of target organ damage (TOD) and no additional ASCVD risk factors, are classified as ‘moderate risk’ individuals (60).

Another widely used CVD risk calculator is the one proposed by the 2019 American College of Cardiology / American Heart Association guidelines (61). Notably, these consider POI as a CVD risk enhancing factor, which necessitates statin therapy in adults 40–75 years without DM and 10-year CVD risk of 7.5–19.9% (61).

Lp(a) assessment should also be assessed at least once in a person’s lifetime (57), since it may further increase...
ASCVD risk, in cases with concentrations >50 mg/dl (>120 nmol/L). Moreover, if these exceed 180 mg/dl (>430 nmol/L), the CVD risk is equivalent to that FH is associated with (57).

Statins, either alone or with ezetimibe, constitute the lipid-lowering treatment of choice in patients at ‘very high’ or ‘high’ ASCVD risk. In cases who cannot achieve these LDL-C targets, proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors (evolocumab or alirocumab) may be added. In cases with hypertriglyceridemia (135–499 mg/dl (1.5–5.6 mmol/L)), despite statin treatment, and high or very high CVD risk, a fibrate or high dose icosapentyl-fatty acid (4 g/day) should be added (57). Statins may be also considered for individuals <40 years of age with DM and TOD or LDL-C >100 mg/dl (2.5 mmol/L) (60).

In all cases, adoption of a Mediterranean dietary pattern, regular exercise, smoking cessation and alcohol restriction to a maximum of 100 g/week, is recommended (60). BP should be lowered to <140/90 mm Hg in all patients. In treated patients aged <69 years, the target range of systolic BP (SBP) is 120–130 mm Hg, whereas in those ≥70 years, the goal for SBP is <140 mm Hg or even <130 mmHg, if tolerated. Diastolic BP should be lowered to <80 mm Hg in all treated patients (60). In patients with DM at ‘high’ or ‘very high’ CVD risk, low-dose aspirin may be administered for primary prevention (60).

Based on these guidelines, an algorithm of CVD risk assessment and personalized intervention in postmenopausal women aged <50 or 50–69 years old, is illustrated in Fig. 1.

Conclusions

In conclusion, transition to menopause predisposes the woman to increased CVD risk, due to visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, NAFLD and hypertension. However, whether menopause per se is associated with a higher risk of CVD events has not been proven. On the other hand, both EM and POI are associated with increased CVD morbidity and mortality, mainly attributed to IHD. MHT ameliorates most of the traditional CVD risk factors, with different effects, depending on the type, dose, route of administration and type of progestogen. MHT may reduce the risk of CVD events if prescribed within 10 years since the FMP or in postmenopausal women <60 years old and at low-moderate CVD risk. However, MHT should currently not be prescribed for the sole purpose of CVD prevention. In any case, there is an exigent need for well-designed RCTs with the newer regimens, such as transdermal estrogen and micronized progesterone, to prove their efficacy and safety in terms of CVD and breast cancer risk.

Declaration of interest

Prof. Stevenson has received grants/research support from Abbott, Mylan and Pfizer; consulting fees from Abbott, Mylan and Pfizer; and speaker’s honoraria from Abbott, Bayer, Gedeon Richter, Menarini, Mylan, and Pfizer. The other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

1 European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Brussels, Belgium: European Heart Network, 2017. (available at: http://www.ehnheart.org/cvd-statistics/cvd-statistics-2017.html)
2 Maas AHEM, Rosano G, Chieffo A, van Dijken D, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European Cardiologists, Gynaecologists, and Endocrinologists. European Heart Journal 2021 42 967–984. (https://doi.org/10.1093/eurheartj/ehaa1044)
3 Stevenson JC, Collins P, Hamoda H, Lambrinoudaki I, Maas AHEM, Maclaran K & Panay N. Cardiometabolic health in premature ovarian insufficiency. Climacteric 2021 24 474–480. (https://doi.org/10.1111/j.1749-6632.2020.13697.137.2021.190232)
4 Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ & STRAW+10 Collaborative Group. Executive summary of the stages of reproductive aging workshop+10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology and Metabolism 2012 97 1159–1168. (https://doi.org/10.1210/jc.2011-3362)
5 Anagnostis P & Goulios DG. Menopause and its cardiometabolic consequences: current perspectives. Current Vascular Pharmacology 2019 17 543–545. (https://doi.org/10.2174/157016111799190228123233)
6 Anagnostis P, Paschou SA, Katsiki N, Krikidis D, Lambrinoudaki I & Goulios DG. Menopausal hormone therapy and cardiovascular risk: where are we now? Current Vascular Pharmacology 2019 17 564–572. (https://doi.org/10.2174/157061116661807090951348)
7 Mauvais-Jarvis F, Manson JE, Stevenson JC & Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocrine Reviews 2017 38 173–188. (https://doi.org/10.1210/er.2016-1146)
8 Toth MJ, Tchernof A, Sies CJ & Poehlman ET. Menopause-related changes in body fat distribution. Annals of the New York Academy of Sciences 2000 904 502–506. (https://doi.org/10.1111/j.1749-6632.2000.1006506.x)
9 Abdillgaard P, Ploug T, Al-Saoudi E, Wagner T, Thomsen C, Ewertsen C, Bzorek M, Pedersen BK, Pedersen AT & Lindegaard B. Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass. Scientific Reports 2021 11 14750. (https://doi.org/10.1038/s41598-021-94189-2)
10 Price TM, O’Brien SN, Welter BH, George R, Anandiwal J & Kilgore M. Estrogen regulation of adipose tissue lipoprotein lipase
Menopause and cardiovascular disease

Anagnostis P, Karras S, Lambrinoudaki I, Stevenson JC & Goulis DG. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. International Journal of Clinical Practice 2016 70 967–977. (https://doi.org/10.1111/i.jcp.12903)

Rodeva R, Mladenovic D, Veskovka M, Hrcinc D, Bjeckic-Macut J, Stanojlović O, Livadas S, Yildiz BO & Macut D. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas 2021 151 22–30. (https://doi.org/10.1016/j.maturitas.2021.06.012)

Venetasani V & Polyzos SA. Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic perspectives. Current Vascular Pharmacology 2019 17 546–555. (https://doi.org/10.2174/175706116666180711121949)

Wang Z, Xu M, Hu Z & Shrestha UK. Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index. Menopause 2015 22 667–673. (https://doi.org/10.1097/GME.0000000000000352)

Kannel WB, Hjortland MC, McNamara PM & Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Annals of Internal Medicine 1976 85 447–452. (https://doi.org/10.1001/jama.1976.02190030047044)

Kannel T, Gordon WB, Hjortland MC & McNamara PM. Menopause and coronary heart disease. The Framingham Study. Annals of Internal Medicine 1978 89 157–161. (https://doi.org/10.7326/0003-4819-89-2-157)

Colditz GA, Willett WC, Stamper MJ, Rosner B, Speizer FE & Hennekens CH. Menopause and the risk of coronary heart disease in women. New England Journal of Medicine 1987 316 1105–1110. (https://doi.org/10.1056/NEJM198704303161801)

Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, Kavousi M & Franco OH. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiology 2016 1 767–776. (https://doi.org/10.1001/jamacardio.2016.2415)

Tao XY, Zhu AZ, Wang JG & Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric 2016 19 27–36. (https://doi.org/10.1080/13697137.2015.1094784)

Roeters van Lennep JE, Heida KY, Bots ML, Hoek A & collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. European Journal of Preventive Cardiology 2016 23 178–186. (https://doi.org/10.1177/2047487314556004)

Honigberg MC, Zekavat SM, Arajam K, Finneran I, Klarin D, Bhatt DL, Januzzi JL Jr, Scott NS & Natarajan P. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA 2019 322 2411–2421. (https://doi.org/10.1001/jama.2019.19191)

Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godlis IE, Lambrinoudaki I, Theodorou M & Goulis DG. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis. Maturitas 2017 99 27–36. (https://doi.org/10.1016/j.maturitas.2017.02.009)

ACOG committee opinion no. 556: postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstetrics and Gynecology 2013 121 887–890. (https://doi.org/10.1097/AOG.0000428645.90795.d9)

Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV & Santen RJ. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2015 100 3975–4011. (https://doi.org/10.1210/jc.2015-2236)
Menopause and cardiovascular disease

49 Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Hwang-Bo, et al. Menopause and cardiovascular disease. Maturitas 2020 135 82–88. (https://doi.org/10.1016/j.maturitas.2020.03.007)

40 Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernst VL & Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine 1992 117 1016–1037. (https://doi.org/10.7326/0003-4819-117-10-1016)

51 Panay N, Hamoda H, Arya R, Savvas M & British Menopause Society & Women’s Health Concern. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause International 2013 19 59–68. (https://doi.org/10.1177/1743874613489645)

52 Schenck-Gustafsson K, Brincat M, Erel CT, Gambacciani M, Lambrinoudaki I, Moen MH, Tremollieres F, Vujovic S, Rozenberg S, Rees M, et al. EMAS position statement: managing the menopause in the context of coronary heart disease. Maturitas 2013 78 94–97. (https://doi.org/10.1016/j.maturitas.2010.10.005)

53 Mikkola TS, Tuomikoski P, Lytyinen H, Korhonen P, Hoti I, Vattulainen E, Gissler M & Vilkokkala O. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. Journal of Clinical Endocrinology and Metabolism 2015 100 4588–4594. (https://doi.org/10.1210/jc.2015-1864)

54 Asi N, Mohammad K, Haydour Q, Gionfriddo MR, Vargas OL, Prokop LJ, Faubion SS & Murad MH. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Systematic Reviews 2016 5 121. (https://doi.org/10.1186/s13643-016-0294-5)

55 Stute P, Wildt L & Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric 2018 21 111–122. (https://doi.org/10.1177/1368865217735161)

56 Ioannis P, Winter-Ozogewska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremem JK, Cano A, Chedraui P, Goulis DG, Lopes P, et al. Menopause and diabetes: EMAS clinical guide. Maturitas 2018 117 6–10. (https://doi.org/10.1016/j.maturitas.2018.08.009)

57 Mach F, Raigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020 41 111–188. (https://doi.org/10.1093/eurheartj/ehz455)

58 SCORE2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal 2021 42 2439–2454. (https://doi.org/10.1093/eurheartj/ehab309)

59 SCORE2-OP Working Group and ESC Cardiovascular Risk Collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal 2021 42 2455–2467. (https://doi.org/10.1093/eurheartj/ehab312)

60 Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Biffi A, Boavida JM, Capodanno D, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2021 42 3227–3337. (https://doi.org/10.1093/eurheartj/eurh848)

61 Grundy SM, Stone NJ, Bailey AL, Beam C, Birnher KK, Blumenthal RS, Braun LT, de Ferranti S, Faia-A-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVR/P/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2019 139 e1082–e1143. (https://doi.org/10.1161/CIR.0000000000000625)

Received in final form 28 February 2022
Accepted 8 March 2022
Accepted Manuscript published online 8 March 2022